Search

Search Results

• Severe drug hypersensitivity syndrome due to sulphasalazine in patient with rheumatoid arthritis

  M. Gutierrez, E. Filippucci, L. Bugatti, C. Bertolazzi, W. Grassi

  65-68

  https://doi.org/10.4081/reumatismo.2009.65

  1551

  PDF: 1149

• PO:11:162 | DRESS syndrome: a case treated with mepolizumab Alessandro Belotti Masserini¹, Stefania Bertocchi¹, Eleonora Bruschi¹, Silvia Breda¹, Valeria Rossi¹, Elide Lupi¹, Tania Ubiali¹, Fabrizio Angeli¹, Massimiliano Limonta¹ | ¹ASST Papa Giovanni XXIII, Bergamo, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2152

  150
• 

  Voriconazole-induced periostitis

  D.C. Fernández Ávila, M. Diehl, A.M. Degrave, M. Buttazzoni, T. Pereira, M.A. Aguirre, A.L. Basquiera, M. Scolnik

  44-47

  19-04-2021

  https://doi.org/10.4081/reumatismo.2021.1368

  4433

  PDF: 956

• PO:19:287 | Cardiac involvement in Still’s disease: a challenge in differential diagnosis Ludovica Manisera¹, Martina Dodaro², Giuseppe Norcia³, Angelica Gattamelata⁴, Nicola Galea⁵, Concetta Torromeo⁶, Gaetano Tanzilli⁷, Fabrizio Conti⁸, Roberta Priori⁹ | ¹Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Università degli Studi di Roma La Sapienza, Roma; ²Dipartimento di Medicina Traslazionale e di Precisione, Università degli Studi di Roma La Sapienza, Roma; ³Dipartimento di Medicina Molecolare, Università degli Studi di Roma La Sapienza, Roma, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2173

  145
• 

  Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case

  V. Shobha, A.M. Desai, T. Matthew

  99-102

  09-07-2019

  https://doi.org/10.4081/reumatismo.2019.1115

  1471

  PDF: 958
• 

  Acute lung injury timely associated with the administration of tocilizumab

  Alojzija Hočevar, Anja Srpčič, Katja Lakota, Miša Fister

  29-01-2026

  https://doi.org/10.4081/reumatismo.2026.1947

  999

  PDF: 46
• 

  After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica?

  Ciro Manzo, Marco Isetta

  03-03-2025

  https://doi.org/10.4081/reumatismo.2025.1823

  1534

  PDF: 246